CyTOF analysis of novel mucosal immune cells in Inflammatory bowel disease: relation with disease phenotype and location.
- Conditions
- inflammatory bowel disease. Chronic bowel disease10017969
- Registration Number
- NL-OMON50535
- Lead Sponsor
- Maag-Darm- en Leverziekten
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 220
Age 10-40 years, with the following phenotype are to be included:
with the following phenotype are to be included:
- 50 control patients
- 85 patients with ulcerative colitis
- 85 patients with crohn's disease
Within this group of 170 IBD patients (85 CD and UC patients) patients these
patients will be included as well:
Patiens age 18-40 years with L1 Crohn's disease with in the history an
ileocecal resection and since operation naive for immunosuppessive medication.
During endoscopy an active Crohn's diases is diagnosed.
Patients age 18-40 years old with ulcerative colitis with in the past an
ileoanal pouch procedure.
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
* No informed consent
* Insufficient knowledge of Dutch language and/or inability to understand the
information provided
* Children aged between 12 and 18 years who are unable to understand the
information provided.
* If a patient or control suffer from other immune mediated diseases as
well: rheumatoid artritis, psoriasis, hidradenitis suppurativa.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1. Characterisation of the cell populations associated with the different IBD<br /><br>fenotypes (CU or CD L1, L2, L3, L4).<br /><br>2. Comprehensive phenotypic analysis and comparison of mucosal immune<br /><br>compartment in patients and controls ex vivo (year 1-3);<br /><br>3.Comprehensive phenotypic analysis and comparison of mucosal stromal cell<br /><br>compartment in patients and controls ex vivo (year 1-3) </p><br>
- Secondary Outcome Measures
Name Time Method <p>a. Comparison of immune and stromal cell compartments between pediatric and<br /><br>adult patients (year 1-3);<br /><br>b. Determination of correlates between changes in immune and stromal cell<br /><br>compartments and response to therapy (year 2 and 4);<br /><br>c. Comparison of the immune cell compartments between naïve patients and<br /><br>patients with active disease already on treatment to determinate the response<br /><br>on treatment.<br /><br>c. Functional analysis of selected immune and stromal cell subsets based on<br /><br>analysis in the endpoints above (year 3 and 4).</p><br>